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MaOBJECTIVES The aims of this study were to characterize cardiac allograft vasculopathy (CAV) phenotypes
using optical coherence tomography (OCT) and to evaluate the prognostic significance of OCT-determined
CAV severity.
BACKGROUND Intravascular OCT enables in vivo characterization of CAV microstructure after heart transplantation.
METHODS Sixty-two patients undergoing heart transplantation were enrolled at routine angiography from September
2013 through October 2015 and prospectively followed until censoring on May 27, 2016. Optical coherence tomographic
acquisitions aimed for the longest possible pull-backs, including proximal segments of all 3 major vessels. Plaques and
bright spots were analyzed by delineating circumferential borders and measuring the angulation of total circumference.
Layers were contoured for absolute and relative estimates. Nonfatal CAV progression (NFCP) during follow-up was
registered. NFCP included occluded vessels or severe ($70%) new angiographic coronary stenosis or percutaneous
coronary intervention.
RESULTS A total of 172 vessels were categorized as follows: no CAV, n ¼ 111; mild to moderate CAV (<70%
stenosis), n ¼ 40; and severe CAV ($70% stenosis), n ¼ 21. Layered fibrotic plaque (LFP) was the most prevalent
plaque component, and the extent increased with angiographic CAV severity (p < 0.01). During follow-up, 22 of 172
vessels (13%) experienced NFCP. Median follow-up was 633 days (interquartile range: 432 to 808 days). The
extent of LFP (hazard ratio: 5.0; 95% confidence interval: 2.1 to 12.4; p < 0.0001) and the extent of bright spots
(hazard ratio: 6.2; 95% confidence interval: 2.4 to 15.8, p < 0.001) were strong predictors of NFCP. By
combining LFP and bright spots, a strong NFCP predictive model was obtained (hazard ratio: 8.9; 95%
confidence interval: 2.6 to 29.9; p < 0.0001).
CONCLUSIONS OCT enables the detection of CAV-associated plaque compositions and allows early detection and
differentiation of vessel wall disease not visible on angiography. LFP was the most prevalent plaque component, was
strongly associated with NFCP, and may be associated with stepwise CAV progression caused by organizing mural
thrombi. (The GRAFT Study: Evaluation of Graft Function, Rejection and Cardiac Allograft Vasculopathy in First Heart
Transplant Recipients; NCT02077764) (J Am Coll Cardiol Img 2017;10:773–84) © 2017 by the American College of
Cardiology Foundation.m the aDepartment of Cardiology, Aarhus University Hospital, Skejby, Denmark; and the bDivision of Image Processing, Leiden
iversity Medical Centre, Leiden, the Netherlands. Funding was received from the Health Research Fund of Central Denmark
gion and the Danish Heart Association. The authors have reported that they have no relationships relevant to the contents
this paper to disclose.
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ABBR EV I A T I ON S
AND ACRONYMS
CAV = cardiac allograft
vasculopathy
CI = confidence interval
HTx = heart transplantation
ICC = intraclass correlation
coefficient
IQR = interquartile range
IVUS = intravascular
ultrasound
LAD = left anterior descending
coronary artery
LFP = layered fibrotic plaque
NFCP = nonfatal cardiac
allograft vasculopathy
progression
OCT = optical coherence
tomography
RCA = right coronary artery
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774C ardiac allograft vasculopathy (CAV)remains the most important long-term cardiac mortality cause after
heart transplantation (HTx) (1). Autopsy
studies describe CAV as a combination of
atherosclerosis, concentric fibrotic intimal
thickening, thrombosis, and inflammation
(2,3). Most transplantation centers routinely
perform coronary angiography to determine
CAV severity and progression. However, con-
ventional angiography often misses or un-
derestimates the CAV burden. Hence,
intravascular ultrasound (IVUS) diagnoses
CAV in approximately 50% of HTx patients
with normal results on angiography (4–8).
IVUS is therefore widely used in HTx patients
(9). In recent years, optical coherence tomog-
raphy (OCT) has become the state-of-the-art
high-resolution intravascular imaging mo-
dality for the assessment of coronary disease.IVUS and OCT detect CAV equally well when tradi-
tional IVUS parameters are used (10,11) (i.e., maximal
intimal thickness and intima/media ratio). However,
OCT provides 10-fold greater spatial resolution than
IVUS and enables a more detailed evaluation of vessel
wall microstructure. The use of OCT may therefore
offer important, thus far undetectable in vivo insights
into the nature and pathogenesis of CAV. If OCT
enables differentiation among various vessel wall
pathologies, it may be used for early detection of
CAV and for CAV staging on the basis of coronary
disease phenotypes.SEE PAGE 785In the present study, we characterized CAV phe-
notypes using OCT, evaluated the utility of OCT for
CAV severity assessment, and determined the prog-
nostic significance of CAV severity.
METHODS
PATIENTS. Patients undergoing routine angiography,
right-heart catheterization, and echocardiography
were included from September 6, 2013 through
October 19, 2015. Patients $18 years of age with
creatinine levels <200 mmol/l were included after
providing informed written consent according to
the principles of the Declaration of Helsinki.
The Central Denmark Region Committees on
Biomedical Research Ethics approved the study.
The study was registered with ClinicalTrials.gov
(NCT02077764).
Patients were prospectively followed from the time
of OCT until death or censoring on May 27, 2016.Nonfatal CAV progression (NFCP) during follow-up
was registered. NFCP included: 1) severe new coro-
nary stenosis ($70%) with or without percutaneous
intervention; and 2) clinically suspected coronary
spasm verified by angiography and/or electrocardi-
ography. Patients who experienced NFCP were strat-
ified at the time of their first NFCP episode.
CORONARY ANGIOGRAPHY AND OCT. Image
acquisition. Coronary angiography was performed us-
ing a 6-F guiding catheter after administration of
intracoronary nitroglycerin (200 mg) into the left main
coronary artery and right coronary artery (RCA). At
least 2 projections of each coronary artery were
acquired.
Prior to OCT recordings, intravenous heparin 5,000
IU was administered. OCT was performed using
Lunawave OCT (Terumo, Tokyo, Japan), aiming for
the longest possible pull-backs and ensuring acqui-
sition of proximal segments covering up to 150 mm of
each major branch. Pull-back speed was adjusted to
optimize the scan time to 3 to 4 s during flushing with
15 to 20 ml contrast. In case of inadequate image
quality, the recordings were repeated after guiding
catheter position adjustment. Recordings were ob-
tained in the left main coronary artery, the left
anterior descending coronary artery (LAD), the
circumflex coronary artery, and the RCA.
Image analysis. Angiographic CAV assessment. All ma-
jor branches with visual CAV were analyzed offline
using 2-dimensional quantitative coronary analysis
with QAngioXA 7.3 (Medis Medical Imaging, Leiden,
the Netherlands). The reference vessel size and the
maximal stenosis severity of each vessel were
measured. Vessels were divided into 3 angiographic
CAV groups by the severity of the stenosis according
to guidelines from the International Society for Heart
and Lung Transplantation (9): CAV 1 (mild),
angiographic left main <50% or primary vessel or
branch stenosis with a maximum lesion of <70%;
CAV 2 (moderate), angiographic left main <50%, a
single primary vessel $70%, or isolated branch
stenosis $70% in branches of 2 systems; CAV 3
(severe), angiographic left main $50%, 2 or more
primary vessels $70% stenosis, or isolated branch
stenosis $70% in all 3 systems; or CAV 1 or CAV 2
with allograft dysfunction (defined as left ventricular
ejection fraction <45%) or evidence of significant
restrictive physiology (symptomatic patients with
ratio of early to late ventricular filling velocities >2,
isovolumetric relaxation time <60 ms, E-wave
deceleration time <150 ms, right atrial pressure
>12 mm Hg, pulmonary capillary wedge pressure
>25 mm Hg, or cardiac index <2 l/min/m2). Because
FIGURE 1 Quantitative Optical Coherence Tomographic Vessel Layer and Plaque Analysis
(A) Normal vessel; (A0) vessel layer analysis. (B) Intimal hypertrophy; (B0) vessel layer analysis. (C) Lipid plaque; (C0) lipid plaque with plaque
analysis. Green ring and arrow indicate media-adventitia interface; pink ring and arrow denote intima-media interface; red ring and arrow
denote luminal border; the yellow ring and arrow indicate plaque and plaque angle.
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775we could not discriminate between CAV 2 and CAV 3 in
per-vessel analysis, we combined these groups.
Furthermore, vessels with previous percutaneous
intervention were classified as CAV 2 and 3 despite
no present diameter stenosis $70%.OCT analysis. Quantitative analysis was performed
at 1-mm intervals using a customized version
of the validated QCU-CMS analysis software
(Medis Medical Imaging). Figure 1 shows quantitative
OCT analysis. Vessel layer assessment included
FIGURE 2 Range of Optical Coherence Tomographic Findings in the Heart Transplantation Study Population
(A) Bright spots between 8 o’clock and 6 o’clock; (B) circumflex bright spots; (C) thin circumferential calcifications; (D) intimal microvessels;
(E) side branch ostium with narrowing caused by fibrotic plaque formation; (F) coronary spasm identified by bulging intima and clamped side
branch; (G) intraluminal thrombosis; (H) erosions and intraluminal thrombi; (I) plaque rupture.
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776measurements of luminal area, intimal area, and
medial area. These parameters were obtained from
3 vessel contours: a lumen-intima interface contour,
an intima-media interface contour, and a media-
adventitia interface contour (Figures 1A and 1B).
Plaque and bright-spot analysis was performed by
delineating lateral plaque borders (Figure 1C), thereby
measuring the angulation of circumferential plaque,
and reporting the percentage of total circumference
in analyzed frames. Plaques were classified as: 1) lipid
(combined lipid pools and thin-cap fibroatheromas);
2) calcifications; or 3) layered fibrotic plaques (LFPs).
The lipid plaques were defined as heterogenic,
signal-poor, highly attenuating intimal regions withdiffuse or poorly defined borders. Calcifications were
defined as sharply delineated, heterogeneous, signal-
poor regions. LFP was defined as homogeneous,
signal-rich tissue but predominantly with a signal
intensity lower than surrounding or deeper layers of
intimal tissue and with a clearly layered structure.
LFP could be identified as a separate plaque
component superficial to other plaque types (lipid
plaque, calcified plaque). Bright spots were defined
as signal-rich attenuating regions within the intima
layer and a signal intensity exceeding that of
adjacent fibrotic tissue. Adaptions were based on
Tearney et al. (12). Figure 2 presents typical OCT
findings in the analyzed HTx cohort.





CAV 2 and 3
(n ¼ 13) p Value*
Men 74 88 54 0.33
Age, yrs 53  14 52  9 56  12 0.66
Donor age, yrs 40  12 44  14 46  8 0.43
Time since transplantation, yrs 2.0 (1.0–7.0) 8.0 (1.1–11.0) 15.0 (11.0–16.0) <0.001
Diabetes 13 24 8 0.45
Hypertension 90 82 92 0.64
Former PCI treatment 0 0 23 <0.001
Rejection score 7.0 (4.0–11.0) 10 (5.0–12.0) 10.0 (8.0–14.0) 0.08
Medication
Prednisolone 58 47 15 <0.05
Ciclosporine 32 6 69 <0.001
Tacrolimus 68 94 31 <0.001
Everolimus 16 24 54 <0.05
Mycophenolate 90 75 46 <0.01
Statins 87 88 92 0.89
ACE/AT II inhibitor 77 75 69 0.86
Furosemide or bumetanide 19 6 23 0.42
Aspirin 26 63 100 <0.0001
Graft function
Ejection fraction, % 64  10 61  8 59  11 0.20
E/A ratio 2.0  0.6 2.0  1.0 2.1  0.8 0.92
IVRT, ms 65  15 66  22 77  30 0.22
E-wave deceleration time, ms 164  38 163  43 151  56 0.64
Right atrial pressure, mm Hg 4.1  2.4 4.5  4.0 5.9  3.3 0.21
PCWP, mm Hg 10.5  4.4 10.4  5.0 10.6  5.9 0.99
Cardiac index, l/min/m2 2.9  0.5 2.6  0.4 2.7  0.3 0.09
Biochemistry
Creatinine, mmol/l 99 (80–120) 100 (82–116) 120 (80–124) 0.64
Hemoglobin, mmol/l 8.7 (7.6–9.0) 8.4 (7.7–9.3) 8.5 (8.1–9.0) 0.61
Total cholesterol, mmol/l 4.5 (3.7–5.4) 4.7 (4.0–4.9) 5.1 (4.5–6.2) 0.26
Troponin T, ng/l 13 (5–18) 8 (5–17) 14 (5–26) 0.35
NT-proBNP, ng/l 335 (180–678) 249 (137–486) 1203 (397–1,631) <0.05
Values are %, mean  SD, or median (interquartile range). *Testing difference between the 3 groups.
ACE ¼ angiotensin-converting enzyme; AT II ¼ angiotensin II; CAV¼ cardiac allograft vasculopathy; E/A ratio¼
ratio of early to late ventricular filling velocities; IVRT ¼ isovolumetric relaxation time; NT-proBNP ¼ N-terminal
pro–B-type natriuretic peptide; PCI ¼ percutaneous coronary intervention; PCWP ¼ pulmonary capillary wedge
pressure.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 0 , N O . 7 , 2 0 1 7 Clemmensen et al.
J U L Y 2 0 1 7 : 7 7 3 – 8 4 Clinical Value of OCT After HTx
777The vessel layer contours were obtained in areas
with no side branches and no atherosclerosis.
Qualitative analysis involved counting the number
of side branches exceeding 1 mm and the number of
intraluminal thromboses. Furthermore, the vessel
disease phenotype was estimated and characterized
as normal phenotype, thrombofibrotic phenotype,
atherosclerotic phenotype only, and mixed athero-
sclerotic and thrombofibrotic phenotype. The
thrombofibrotic phenotype was defined as 2 or more
areas with LFP, bright spots without lipid plaque
presence, or any combination of these. Atheroscle-
rotic phenotype was defined as 1 or more areas with
lipid plaques.
STATISTICAL METHODS. We analyzed data on a
per-vessel level and a per-patient level. In patient-
level analysis, we used the mean value from
analyzed vessels for each variable.
Normally distributed data are presented as mean 
SD; non-normally distributed data are presented
as median and (interquartile range [IQR]). Categorical
data are presented as absolute values with percent-
ages. Histograms and Q-Q plots were used to
check continuous values for normality of the data
distribution. Between-group differences were
assessed by mixed-model analysis of variance. The
intraclass correlation coefficient (ICC) was used to
determine the correlation of OCT findings between
the LAD, circumflex coronary artery, and RCA.
Sensitivity and specificity were determined using
receiver-operating characteristic curves. Optimal
between-group cutoff points for plaque and
vessel measurements were defined as the intersec-
tion points of sensitivity and specificity on the
receiver-operating characteristic curves. Time-to-
event data were evaluated using Kaplan-Meier
estimates and Cox proportional hazards methods.
Hazard ratios, 95% confidence intervals (CIs), and
2-sided p values were calculated using the Cox
models. A p value <0.05 was considered to
indicate statistical significance. Analyses were
performed using Stata/IC 13 (StataCorp LP, College
Station, Texas).
RESULTS
CLINICAL CHARACTERISTICS. We included 62
patients, of whom 31 had normal vessels by angiog-
raphy (CAV 0), 17 had mild to moderate CAV
by angiography (CAV 1), and 13 had severe CAV by
angiography (CAV 2 and 3). No patients were reclas-
sified as CAV 2 and 3 on the basis of International
Society for Heart and Lung Transplantation graftdysfunction criteria. Table 1 presents the de-
mographics of the angiographic CAV groups.
FEASIBILITY OF OCT. In 1 of the 62 patients we
were unable to obtain analyzable images from any
of the vessels. The analysis included 59 LAD
vessels (95%), 56 circumflex vessels (90%), and
57 RCA vessels (91%). A total of 11,158 frames from 172
vessels were analyzed. No patients had complications
due to angiography or acquisition of OCT.
ANGIOGRAPHIC VESSEL ANALYSIS. The mean
length of the analyzed vessels did not differ between
angiographic CAV groups (CAV 1, 80  20 mm; CAV
2 and 3, 74  21 mm; p ¼ 0.14). Median maximal
stenosis in the CAV groups was 35% (IQR: 30% to 43%)
TABLE 2 Qualitative OCT Analysis, Stratified According to Angiographic CAV Groups
CAV 0 CAV 1 CAV 2 and 3 p Value*
Patient level n ¼ 31 n ¼ 17 n ¼ 13
Number of side branches >1 mm 7.5  0.3 7.2  0.4 4.9  0.4 <0.0001
OCT quality† 4.3  0.1 4.5  0.1 4.4  0.1 0.35
Number of intraluminal thrombi 0.02  0.2 0.12  0.2 1.34  0.2 <0.0001
Number of erosions 0 0.08  0.1 0.68  0.1 <0.0001
Vessel level n ¼ 111 n ¼ 40 n ¼ 21
Number of side branches >1 mm 7.5  0.2 6.1  0.4 4.8  0.5 <0.0001
OCT quality† 4.3  0.1 4.5  0.1 4.6  0.2 0.14
Number of intraluminal thrombi 0.1  0.1 0.3  0.2 2.0  0.3 <0.0001
Number of erosions 0.04  0.1 0.28  0.1 0.65  0.1 <0.0001
Phenotype
Normal 47 3 0 <0.0001
Thrombofibrotic 32 50 52 0.06
Atherosclerotic 10 10 10 0.99
Mixed thrombofibrotic and
atherosclerotic
11 38 38 <0.001
Values are mixed model coefficient  SE or %. *Testing difference between the 3 groups. †On a scale ranging
from 1 (unreadable OCT images) to 5 (optimal image quality).
CAV ¼ cardiac allograft vasculopathy; OCT ¼ optical coherence tomography.
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778(CAV 1) and 76% (IQR: 71% to 83%) (CAV 2 and 3)
(p < 0.0001).
CLINICAL FOLLOW-UP. Median time from OCT
assessment to clinical follow-up was 605 days
(IQR: 373 to 759 days). NFCP occurred in 13% of ves-
sels (22 of 172) and 20% of patients (12 of 61) during
follow-up. One vessel was censored because of acute
myocardial infarction. Twenty-one vessels were
censored because of severe stenosis. The majority
of censored vessels had angiographic CAV. Hence,
2 vessels were classified as CAV 0, 10 vessels as CAV 1,
and 10 vessels as CAV 2 and 3. Percutaneous coronary
intervention was performed in 13 vessels. Likewise,
the majority of censored patients had angiographic
CAV; 1 patient had CAV 0, 2 patients CAV 1, and
9 patients had CAV 2 and 3.
QUALITATIVE OCT ANALYSIS: PATIENT LEVEL. Table 2
displays the qualitative OCT results on the patient
level. The number of side branches exceeding 1 mm in
diameter decreased significantly, whereas the num-
ber of fresh luminal thrombi and erosions increased
significantly with increasing angiographic CAV
severity (p < 0.0001).
QUALITATIVE OCT ANALYSIS: VESSEL LEVEL. Table 2
displays the qualitative OCT results on the vessel
level. Fresh luminal thrombi or plaque ruptures
were observed in 7 CAV 0 vessels (6%), 9 CAV 1
vessels (23%), and 9 CAV 2 and 3 vessels (38%)
(p < 0.0001).
TheOCT-established qualitative phenotypes inmild
to moderate CAV and in the severe CAV groups werecomparable, with the majority of vessels showing the
thrombofibrotic phenotype (50% and 52%) or a mix of
the thrombofibrotic and atherosclerotic phenotypes
(38% and 38%). Importantly, 53% of vessels with no
angiographic CAV had abnormal phenotype by OCT,
with thrombofibrotic phenotype being the most prev-
alent (32%). We found that vessels with the thrombo-
fibrotic phenotype (p < 0.001) or a mix of
thrombofibrotic and atherosclerotic phenotypes (p <
0.001) had greater NFCP risk during follow-up than
vessels with normal phenotype. Furthermore, 20 of 22
NFCP episodes were seen in vessels with either
thrombofibrotic or a mix of thrombofibrotic and
atherosclerotic phenotypes.
QUANTITATIVE PLAQUE ANALYSIS BY OCT:
PATIENT LEVEL. Table 3 shows the quantitative pla-
que results on the patient level. All OCT-detected
plaque categories increased with the severity of
angiographic CAV. However, no difference was seen
in LFP between CAV 1 and CAV 2 and 3 vessels
(p ¼ 0.88).
QUANTITATIVE PLAQUE ANALYSIS BY OCT: VESSEL
LEVEL. Table 3 presents the quantitative plaque re-
sults on the vessel level. Furthermore, Figure 3A shows
the plaque distribution in the 3 CAV vessel groups. For
all plaque categories, the extent of plaque assessed by
OCT increased with the severity of angiographic CAV.
However, no difference was found between CAV
0 vessels and CAV 1 vessels regarding the extent of LFP
(p ¼ 0.55), bright spots (p ¼ 0.90), and calcifications
(p ¼ 0.20). In contrast, CAV 2 and 3 vessels had a
significantly higher lipid plaque extent than CAV 1
vessels (p < 0.0001). We found a strong NFCP predic-
tive ability for the extent of calcifications, bright spots,
and LFP (Figure 3B). Interestingly, LFPs were the most
prevalent plaque component. These plaques were
seen on the surface of lipid plaques and calcified pla-
ques, but they were more prevalent in segments with
no other advanced plaques (Figure 4). By combining
the extent of LFP (cutoff 9.6%) and bright spots (cutoff
7.9%), we obtained a strong NFCP predictive model
(hazard ratio: 8.9; 95% CI: 2.6 to 29.9; p < 0.0001).
Bright spots $7.9% or LFP $9.6% was seen in 77 ves-
sels. The remaining 95 vessels had <5.5% bright spots
and <8.8% LFP. The vessels with increased NFCP risk
consisted of 31 CAV 0 vessels, 28 CAV 1 vessels, and 18
CAV 2 and 3 vessels. The risk-stratified vessels were
applied at the patient level. Patients who were at
increased NFCP risk included 15 patients with no
angiographic CAV (48% of CAV 0 patients), 10 patients
with mild to moderate CAV (59% of CAV 1 patients),
and 13 patients with severe CAV (100% of CAV 2 and 3
patients).
TABLE 3 Quantitative OCT Analysis, Stratified According to Angiographic CAV Groups
CAV 0 CAV 1 CAV 2 and 3 p Value*
Patient level n ¼ 31 n ¼ 17 n ¼ 13
Length, mm 75  2 79  3 69  4 0.16
Plaque analysis, frame level
Lipid pools, %† 1.7  1.4 4.8  2.0 15.9  2.2 <0.0001
Calcifications, %† 0.3  0.5 2.0  0.7 3.7  0.8 <0.01
Layered fibrotic plaque, %† 3.3  1.9 15.6  2.5 15.0  2.9 <0.0001
Bright spots, %† 2.9  2.1 7.6  3.0 29.3  3.3 <0.0001
Areas
Luminal area, minimal, mm2 5.3  0.3 4.0  0.5 4.2  0.5 <0.05
Luminal area, mean, mm2 9.3  0.4 7.9  0.5 8.6  0.6 0.11
Intimal area, maximal, mm2 3.9  0.4 5.7  0.5 7.7  0.6 <0.0001
Intimal area, mean, mm2 1.8  0.3 2.8  0.4 4.9  0.4 <0.0001
Medial area, mean, mm2 1.0  0.1 1.1  0.1 1.2  0.1 0.21
Ratios
Lumen/intima, mean 6.1  0.3 3.9  0.4 2.3  0.4 <0.0001
Intima/media, mean 1.7  0.1 2.5  0.2 4.0  0.2 <0.0001
Vessel level n ¼ 111 n ¼ 40 n ¼ 21
Length, mm 77  2 75  4 68  5 0.29
Plaque analysis, frame level
Lipid pools, %† 4.3  1.2 5.8  1.3 11.8  1.7 <0.0001
Calcifications, %† 1.1  0.4 2.0  0.5 2.6  0.6 <0.05
Layered fibrotic plaque, %† 7.2  1.6 12.4  1.9 13.9  2.6 <0.01
Bright spots, %† 8.5  2.0 12.4  2.3 12.1  2.9 0.11
Areas
Luminal area, minimal, mm2 5.0  0.3 4.4  0.4 3.2  0.6 <0.05
Luminal area, mean, mm2 9.0  0.3 8.4  0.5 7.9  0.7 0.25
Intimal area, maximal, mm2 4.6  0.3 5.9  0.4 6.9  0.6 <0.001
Intimal area, mean, mm2 2.1  0.2 3.3  0.3 4.6  0.4 <0.0001
Medial area, mean, mm2 1.1  0.0 1.1  0.1 1.2  0.1 0.40
Ratios
Lumen/intima, mean 5.1  0.3 4.3  0.3 3.3  0.4 <0.0001
Intima/media, mean 1.8  0.1 2.9  0.2 4.0  0.2 <0.0001
Values are mixed model coefficient  SE. *Testing difference between the 3 groups. †Mean percentage of
circumference angle.
CAV ¼ cardiac allograft vasculopathy.
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779QUANTITATIVE VESSEL LAYER THICKNESS
ANALYSIS BY OCT: PATIENT LEVEL. The quantita-
tive vessel layer analysis on the patient level is shown
in Table 3. No difference in minimal luminal area was
observed between the groups. In contrast, lumen/in-
tima ratio, intima/media ratio, and intimal area were
significantly altered with increasing angiographic
CAV severity.
QUANTITATIVE VESSEL LAYER THICKNESS
ANALYSIS BY OCT: VESSEL LEVEL. The results of
quantitative vessel layer analysis are shown in
Table 3. Minimal luminal area was significantly
lower in the CAV 2 and 3 vessels than in the CAV
0 and CAV 1 vessels. No difference in minimal lumi-
nal area was seen between CAV 0 and CAV 1 vessels
(p ¼ 0.22). Likewise, no between-group differences
were observed regarding media layer area. In contrast,
intima layer area increased significantly with the
severity of angiographic CAV. Additionally, intima/
media ratio increased with the severity
of angiographic CAV. Furthermore, lumen/intima ratio
decreased with the severity of angiographic CAV. We
found a strong correlation between NFCP and intimal
thickness. Subsequently, intima/media ratio and
lumen/intima ratio also predicted NFCP (Figure 5B).
PREDICTION OF NFCP BY QUANTITATIVE OCT. Table 4
show the NFCP predictive ability of quantitative OCT
parameters on the per-patient and per-vessel levels.
In the unadjusted analysis, calcifications, LFP,
bright spots, intimal area, intima/media ratio, and
lumen/intima ratio all predicted NFCP on both the
per-patient and per-vessel levels. After adjustment
of time since HTx and angiographic CAV class, LFP
showed borderline significant NFCP predictive value
(p ¼ 0.06). Intimal area, lumen/intima ratio, and
intima/media ratio continued to show significant
NFCP predictive value after adjustment.
INTRAOBSERVER AND INTEROBSERVER VARIATION
AND THE CORRELATION BETWEEN MAJOR
CORONARY VESSELS. In comparison of the 3 vessels,
ICC analysis showed a moderate correlation between
the extent of lipid plaques (ICC ¼ 0.84; 95% CI: 0.77
to 0.89), LFP (ICC ¼ 0.74; 95% CI: 0.63 to 0.82),
and bright spot distribution (ICC ¼ 0.83; 95% CI: 0.76
to 0.89). A good correlation was seen comparing
lumen/intima ratio between the 3 major vessels
(ICC ¼ 0.84; 95% CI: 0.77 to 0.90). Finally, a moderate
correlation was seen between the intima/media ratio
when the 3 major vessels were compared (ICC ¼ 0.69;
95% CI: 0.56 to 0.79).
Intraobserver and interobserver variation was
based on the analysis of 378 frames from 5 patients.The results are presented in Table 5. Despite the small
sample, ICCs for both plaque and vessel wall
measurements seemed sound, even though some
variation was noted in the plaque analysis.
DISCUSSION
We describe a comprehensive OCT evaluation of
all 3 major coronary arteries in HTx patients. We
found that angiographic CAV was a manifestation
of 3 main components: regular atherosclerotic pla-
ques, LFP, and bright spots. Using OCT,wewere able to
reclassify the population of HTx patients according to
vessel and plaque components. OCT showed that 66%
of HTx patients had a high degree of adverse vessel
wall components, which is clearly associated with








































































































CAV 0 CAV 1 CAV 2−3
BA
HR 3.7, 95% CI 1.5 to 9.1, p = 0.005
0 200 400 600 800 1000
Days
Lipid Plaques (LP)
HR 8.0, 95% CI 2.9 to 21.6, p < 0.001
0 200 400 600 800 1000
Days
Calcifications (CA)
HR 6.2, 95% CI 2.4 to 15.8, p < 0.001
0 200 400 600 800 1000
Days
Bright Spots (BS)
HR 5.0, 95% CI 2.1 to 12.4, p = 0.001
0 200 400 600 800 1000
Days
Layered Fibrotic Plaques (LFP)
Non-fatal Coronary Events
BS < 7.7%, n = 116
BS > 7.7%, n = 56
LFP < 9.6%, n = 116
LFP > 9.6%, n = 56
LP < 3.4%, n = 108
LP > 3.4%, n = 64
CA < 0.4%, n = 118
CA > 0.4%, n = 54
(A) Margin plots with 95% confidence interval (CI) demonstrating difference between cardiac allograft vasculopathy (CAV) groups regarding lipid plaques (LP),
calcifications (CA), bright spots (BS), and layered fibrotic plaques (LFP). (B) Kaplan-Meier curves and hazard ratios (HRs) for the prognostic value of the
plaque components.
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780increased NFCP risk. LFP and bright spots were the
quantitatively most important plaque components in
graft vasculopathy and were strongly associated with
NFCP. Asymptomatic plaque rupture and intraluminal
thrombi were also observed.
The ability to detect plaque morphology in vivo
seems essential for HTx patients because their coro-
nary disease is often different from traditional
atherosclerotic coronary heart disease. Though prom-
ising, OCT has been used in only a few small 1-vessel
HTx studies (10,11,13–15). Cassar et al. (13) performed
a comprehensive OCT plaque evaluation in the prox-
imal 30 mm of 53 LADs. Interestingly, they found a
high prevalence of lipid pools and complex layered
plaques. The investigators concluded that the
latter may represent repeated thrombosis, which
could be a possible underlying mechanism of
CAV. These findings are of great importance because
they challenge the traditional view that CAV is a dis-
ease characterized by concentric fibrotic intima
thickening. In our study, the most exceptional feature
of the coronary vessel wallmicrostructurewas the high
prevalence of LFP and bright spots. Bright spots are
known to represent macrophages (16), and in HTx
patients they may indicate chronic vascular rejection.An abundance of LFP could suggest the presence of
organized and repeatedmural arterial thrombosis. The
layered appearance with slightly lower signal intensity
of superficial fibrotic layers suggests a relatively young
mural thrombus age. With time, the mural thrombus
may progress to amore organized fibrotic stage leading
to a more homogeneous intimal appearance. This is
noteworthy because intravascular thrombosis in HTx
vessels may be the cause of intimal fibrotic thickness,
loss of side branches, reduced coronary perfusion, and
eventually graft dysfunction and death.
The pathogenesis of mural coronary thrombus
formation in HTx patients remains largely unknown.
Autopsy and IVUS–virtual histology studies of HTx
patients have previously shown a high prevalence of
nonocclusive thrombi (3,17). These thrombi were
layered on discontinuous or absent endothelium
without atheromatous lesions (3). Similarly, in our
study LFPs were observed both with and without
communication to lipid plaques and calcifications.
Hence, underlying plaque erosion may lead to
thrombus formation in some vessels, and local vessel
wall inflammation, here visualized as bright spots,
may be part of this process. However, the underlying
tissue has a normal appearance in many vessels.
FIGURE 4 Morphology of Layered Fibrotic Plaques
(A) Circumflex-layered fibrotic plaque; (B) crescent-shaped layered fibrotic plaque; (C) microvasculature in the interface between the native
intima layer and the added layer of fibrotic tissue; (D) layered fibrotic plaque on the surface of lipid plaque; (E) bright spots on the luminal
surface of layered fibrotic plaque; (F) layered fibrotic plaque on the surface of calcified plaque.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 0 , N O . 7 , 2 0 1 7 Clemmensen et al.
J U L Y 2 0 1 7 : 7 7 3 – 8 4 Clinical Value of OCT After HTx
781Thrombus formation could therefore be triggered by
luminal factors but also by dysfunctional endothelium
due to inflammation at the graft–recipient interface.
Platelets are the cellular mediators of thrombosis, but
they also play an important role in vascular inflam-
mation (18). In our study, the number of intraluminal
thrombi increased with CAV severity. Platelets may
therefore have an important role in the development
of CAV and coronary thrombi in HTx patients (19).
It has been proposed that hypercoagulability and
endothelial dysfunction may be involved in a murine
aortic allograft model in which clopidogrel signifi-
cantly decreased intimal proliferation (20). Likewise,
aspirin in combination with simvastatin significantly
reduced vascular damage and increased survival in a
rat HTx model (21). Future studies should address
whether CAV progression in HTx patients with early
identification of LFP can be reduced by antiplatelet
therapy and anticoagulation therapy.
Our study shows that the phenotypes vary signifi-
cantly in HTx coronary vessel disease. Furthermore,
the correlation of OCT parameters between the 3
major vessels showed noteworthy variation. A
comprehensive OCT evaluation of CAV shouldtherefore involve assessment of all 3 major coronary
arteries. The average contrast use for 3-vessel OCT
was 70 to 90 ml, and the additional procedure time
for OCT was about 10 to 20 min. In our study, no
patients experienced clinically meaningful renal
function deterioration after OCT. However, addi-
tional contrast use must be carefully considered in
HTx patients with more advanced renal dysfunction
than the patients in this study. In contrast to OCT,
IVUS can be performed with minimal contrast use.
CAV screening by IVUS has prognostic value both in
the early (<1 year) (5) and late (>1 year) (4,22) phases
after HTx. Similarly, our study reveals great NFCP
predictive value of vessel wall assessment. The main
advantage of OCT compared with IVUS is the ability to
perform in vivo plaque analysis with microstructure
characterization. Our plaque analysis revealed a high
extent of bright spots and LFP, and the combination
of these components was strongly associated with
NFCP. Therefore, this assessment may be used for
risk stratification and may guide medical therapy.
However, before OCT is recommended as an essential
part of CAV surveillance, future larger studies should
evaluate if OCT-based CAV assessment provides






















































































































CAV 0 CAV 1 CAV 2−3
BA
HR 3.3, 95% CI 1.4 to 7.8, p = 0.013
0 200 400 600 800 1000
Days
Minimal Lumen Area (MLA)
HR 11.2, 95% CI 4.1 to 30.9, p < 0.0001
0 200 400 600 800 1000
Days
Average Intima Area (AIA)
HR 49.1, 95% CI 11.4 to 211.2, p < 0.0001
0 200 400 600 800 1000
Days
Average Lumen/Intima Ratio (ALIR)
HR 21.5, 95% CI 6.3 to 73.1, p < 0.0001
0 200 400 600 800 1000
Days
Average Intima/Media Ratio (AIMR)
Non-fatal Coronary Events
MLA > 3.1 mm2, n = 110
MLA < 3.1 mm2, n = 62
AIA < 3.3 mm2, n = 126
AIA > 3.3 mm2, n = 46
ALIR > 2.5, n = 136
ALIR < 2.5, n = 36
AIMR < 2.9, n = 128
AIMR > 2.9, n = 44
(A) Margins plot with 95% confidence interval (CI) demonstrating difference between cardiac allograft vasculopathy (CAV) groups regarding minimal luminal area
(MLA), average intima area (AIA), average lumen/intima ratio (ALIR), and average intima/media ratio (AIMR). (B) Kaplan-Meier curves and hazard ratios (HRs) for the
prognostic value of the vessels layer parameters.
TABLE 4 Nonfatal Cardiac Allograft Vasculopathy Progression Predictive Ability by Optical Coherence Tomographic Parameters






Lipid plaque 3.6% 0.79 75% 76% 6.5 (1.8–24.1)‡
Calcifications 0.4% 0.77 75% 71% 3.8 (1.2–12.8)†
Layered fibrotic plaque 9.9% 0.82 67% 76% 3.8 (1.2–12.0)†
Bright spots 7.1% 0.84 75% 76% 7.0 (1.9–26.1)‡
Luminal area, minimal 4.0 mm2 0.63 67% 57% 1.0 (0.3–3.0)
Intimal area, mean 2.7 mm2 0.83 75% 76% 9.0 (2.4–33.4)§
Lumen/intima, mean 3.0 mm2/mm2 0.90 83% 84% 10.1 (2.7–37.3)§
Intima/media, mean 2.6 mm2/mm2 0.88 83% 84% 17.1 (3.7–78.5)k
Vessel level
Lipid plaque 3.4% 0.74 68% 67% 3.7 (1.5–9.1)‡ 1.2 (0.5–3.3)
Calcifications 0.4% 0.79 77% 75% 8.0 (2.9–21.6)k 2.5 (0.8–7.1)
Layered fibrotic plaque 9.6% 0.80 73% 73% 5.0 (2.1–12.4)k 2.5 (1.0–6.1)
Bright spots 7.9% 0.82 73% 73% 6.2 (2.4–15.8)k 1.7 (0.6–4.8)
Luminal area, minimal 3.1 mm2 0.70 68% 68% 3.3 (1.4–7.8)† 1.9 (0.8–4.6)
Intimal area, mean 3.3 mm2 0.89 86% 81% 11.2 (4.1–30.9)k 3.8 (1.3–11.3)†
Lumen/intima, mean 2.5 mm2/mm2 0.95 90% 90% 49.1 (11.4–211.2)k 19.5 (3.9–98.0)k
Intima/media, mean 2.9 mm2/mm2 0.92 86% 84% 21.5 (6.3–73.1)k 6.9 (1.7–27.9)‡
*Adjusted for time since heart transplantation and angiographic cardiac allograft vasculopathy class. †p < 0.05. ‡p < 0.01. §p < 0.001. kp < 0.0001.
AUC ¼ area under the curve; CI ¼ confidence interval.
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TABLE 5 Intraobserver and Interobserver Variation
Intraobserver Variation Interobserver Variation
ICC (95% CI) CV Difference ICC (95% CI) CV Difference
Plaque analysis
Calcifications 1.00 (0.99–1.00) 9.5% 0.04  0.6 0.99 (0.96–1.00) 17% 0.6  1.0
Lipid plaques 0.98 (0.89–1.00) 44% 0.4  0.8 1.00 (0.98–1.00) 17% 0.2  0.4
Bright spots 0.97 (0.85–0.99) 31% 1.2  2.6 0.85 (0.46–0.97) 41% 1.3  3.1
Layered fibrotic plaque 0.99 (0.95–1.00) 12% 1.6  3.4 0.98 (0.88–1.00) 23% 4.0  5.7
Vessel layer analysis
Luminal area, minimum 1.00 (1.00–1.00) 0.5% 0.002  0.03 1.00 (1.00–1.00) 2.9% 0.17  0.19
Intimal area, mean 1.00 (1.00–1.00) 0.7% 0.005  0.03 1.00 (1.00–1.00) 1.7% 0.10  0.07
Lumen/intima, mean 1.00 (1.00–1.00) 1.3% 0.04  0.05 0.99 (0.97–1.00) 6.6% 0.25  0.28
Intima/media, mean 0.99 (0.91–1.00) 3.9% 0.07  0.11 0.98 (0.87–1.00) 8.7% 0.46  0.20
CI ¼ confidence interval; CV ¼ coefficient of variation; ICC ¼ intraclass correlation coefficient.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: OCT enables
in vivo characterization of CAV microstructure after HTx and may
be used for risk stratification.We found that CAV is amanifestation
of 3 main components: regular atherosclerotic plaques, LFPs, and
bright spots. LFP is the most prevalent plaque component, is
strongly related to CAV progression during follow-up, and may be
associated with stepwise progression of organized mural thrombi.
TRANSLATIONAL OUTLOOK: Future larger studies should
validate and test if OCT-based CAV assessment provides
prognostic value beyond the standard angiographic assessment.
Furthermore, additional studies should address whether CAV
progression in HTx patients with early identification of LFPs can be
reduced by antiplatelet therapy and anticoagulation therapy.
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783prognostic value beyond the standard angiographic
assessment.
STUDY LIMITATIONS. This study was a single-center
experience in a small cohort of patients. Only 12 pa-
tients experienced NFCP. Therefore, we were unable
to perform multivariable analysis on the patient level.
Furthermore, we do not have histological confirma-
tion of our findings. However, patients were exten-
sively studied using multivessel imaging, and
autopsy studies have previously demonstrated find-
ings similar to ours with a high prevalence of coro-
nary mural thrombosis in HTx patients.
The interobserver and intraobserver analysis was
based on a large number of frames from 5 randomly
selected patients. Thus, it was likely to be influenced
by the particular patients selected, and a larger sample
size is warranted to determine more reliable co-
efficients of variation and ICCs for the OCT parameters.
CONCLUSIONS
OCT provided incremental value to traditional angi-
ography by adding information about plaque
morphology and vessel wall structure. LFP was the
most prevalent plaque component and was found to
be strongly associated with NFCP. The detection of
LFP and bright spots by OCT was identified as a sig-
nificant prognostic marker for the prediction of NFCP.ACKNOWLEDGMENTS The authors thank the nurses
and physicians at the coronary catheterization labo-
ratory for their assistance during optical coherence
tomographic acquisition.
ADDRESS FOR CORRESPONDENCE: Dr. Tor Skibsted
Clemmensen, Department of Cardiology, Aarhus
University Hospital Skejby, Palle Juul-Jensens
Boulevard 99, 8200 Aarhus N, Denmark. E-mail:
torclemm@rm.dk.RE F E RENCE S1. Stehlik J, Edwards LB, Kucheryavaya AY, et al.
The Registry of the International Society for Heart
and Lung Transplantation: 29th official adult heart
transplant report—2012. J Heart Lung Transplant
2012;31:1052–64.
2. Lu WH, Palatnik K, Fishbein GA, et al. Diverse
morphologic manifestations of cardiac allograftvasculopathy: a pathologic study of 64 allograft
hearts. J Heart Lung Transplant 2011;30:
1044–50.
3. Arbustini E, Dal Bello B, Morbini P, Gavazzi A,
Specchia G, Vigano M. Multiple coronary throm-
bosis and allograft vascular disease. Transplant
Proc 1998;30:1922–4.4. Kobashigawa JA, Tobis JM, Starling RC, et al.
Multicenter intravascular ultrasound validation
study among heart transplant recipients: outcomes
after five years. J Am Coll Cardiol 2005;45:1532–7.
5. Tuzcu EM, Kapadia SR, Sachar R, et al. Intra-
vascular ultrasound evidence of angiographically
silent progression in coronary atherosclerosis
Clemmensen et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 0 , N O . 7 , 2 0 1 7
Clinical Value of OCT After HTx J U L Y 2 0 1 7 : 7 7 3 – 8 4
784predicts long-term morbidity and mortality after
cardiac transplantation. J Am Coll Cardiol 2005;
45:1538–42.
6. Tona F, Osto E, Tarantini G, et al. Coronary flow
reserve by transthoracic echocardiography pre-
dicts epicardial intimal thickening in cardiac allo-
graft vasculopathy. Am J Transplant 2010;10:
1668–76.
7. Kass M, Allan R, Haddad H. Diagnosis of graft
coronary artery disease. Curr Opin Cardiol 2007;
22:139–45.
8. Pollack A, Nazif T, Mancini D, Weisz G. Detec-
tion and imaging of cardiac allograft vasculopathy.
J Am Coll Cardiol Img 2013;6:613–23.
9. Mehra MR, Crespo-Leiro MG, Dipchand A,
et al. International Society for Heart and Lung
Transplantation working formulation of a stan-
dardized nomenclature for cardiac allograft
vasculopathy—2010. J Heart Lung Transplant
2010;29:717–27.
10. Khandhar SJ, Yamamoto H, Teuteberg JJ, et al.
Optical coherence tomography for characteriza-
tion of cardiac allograft vasculopathy after heart
transplantation (OCTCAV study). J Heart Lung
Transplant 2013;32:596–602.
11. Garrido IP, Garcia-Lara J, Pinar E, et al. Optical
coherence tomography and highly sensitivity
troponin T for evaluating cardiac allograft vas-
culopathy. Am J Cardiol 2012;110:655–61.12. Tearney GJ, Regar E, Akasaka T, et al.
Consensus standards for acquisition, measure-
ment, and reporting of intravascular optical
coherence tomography studies: a report from the
International Working Group for Intravascular
Optical Coherence Tomography Standardization
and Validation. J Am Coll Cardiol 2012;59:
1058–72.
13. Cassar A, Matsuo Y, Herrmann J, et al. Coro-
nary atherosclerosis with vulnerable plaque and
complicated lesions in transplant recipients: new
insight into cardiac allograft vasculopathy by op-
tical coherence tomography. Eur Heart J 2013;34:
2610–7.
14. Ichibori Y, Ohtani T, Nakatani D, et al.
Optical coherence tomography and intravas-
cular ultrasound evaluation of cardiac allograft
vasculopathy with and without intimal neo-
vascularization. Eur Heart J Cardiovasc Imaging
2016;17:51–8.
15. Dong L, Maehara A, Nazif TM, et al. Optical
coherence tomographic evaluation of transplant
coronary artery vasculopathy with correlation to
cellular rejection. Circ Cardiovasc Interv 2014;7:
199–206.
16. Tearney GJ, Yabushita H, Houser SL, et al.
Quantification of macrophage content in athero-
sclerotic plaques by optical coherence tomogra-
phy. Circulation 2003;107:113–9.17. Matsuo Y, Cassar A, Li J, et al. Repeated epi-
sodes of thrombosis as a potential mechanism of
plaque progression in cardiac allograft vasculop-
athy. Eur Heart J 2013;34:2905–15.
18. Thomas MR, Storey RF. The role of platelets in
inflammation. Thromb Haemost 2015;114:449–58.
19. Modjeski KL, Morrell CN. Small cells, big ef-
fects: the role of platelets in transplant vascul-
opathy. J Thromb Thrombolysis 2014;37:17–23.
20. Abele S, Weyand M, Wollin M, et al. Clopi-
dogrel reduces the development of transplant
arteriosclerosis. J Thorac Cardiovasc Surg 2006;
131:1161–6.
21. Zhu J, Gao B. Simvastatin combined with
aspirin increases the survival time of heart allo-
graft by activating CD4þCD25þ Treg cells and
enhancing vascular endothelial cell protection.
Cardiovasc Pathol 2015;24:173–8.
22. Potena L, Masetti M, Sabatino M, et al. Inter-
play of coronary angiography and intravascular
ultrasound in predicting long-term outcomes after
heart transplantation. J Heart Lung Transplant
2015;34:1146–53.
KEY WORDS cardiac allograft
vasculopathy, heart transplantation,
intravascular imaging, optical coherence
tomography, time-to-event analysis
